Genenta Science S.p.A.

NASDAQ:GNTA

5.45 (USD) • At close November 1, 2024
Bedrijfsnaam Genenta Science S.p.A.
Symbool GNTA
Munteenheid USD
Prijs 5.45
Beurswaarde 99,679,770
Dividendpercentage 0%
52-weken bereik 2.2 - 7.28
Industrie Biotechnology
Sector Healthcare
CEO Mr. Pierluigi Paracchi
Website https://www.genenta.com

An error occurred while fetching data.

Over Genenta Science S.p.A.

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with

Vergelijkbare Aandelen

Pieris Pharmaceuticals, Inc. logo

Pieris Pharmaceuticals, Inc.

PIRS

17.3 USD

Graphite Bio, Inc. logo

Graphite Bio, Inc.

GRPH

3.18 USD

ImmunoPrecise Antibodies Ltd. logo

ImmunoPrecise Antibodies Ltd.

IPA

0.418 USD

Apyx Medical Corporation logo

Apyx Medical Corporation

APYX

1.19 USD

ORIC Pharmaceuticals, Inc. logo

ORIC Pharmaceuticals, Inc.

ORIC

9.41 USD

Gritstone bio, Inc. logo

Gritstone bio, Inc.

GRTS

0.032 USD

CorMedix Inc. logo

CorMedix Inc.

CRMD

9.99 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)